{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:15:38Z","timestamp":1791252938835,"version":"4.1.0"},"reference-count":0,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":510,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2000,8]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Insulin\u2010like growth factors (IGF) and their corresponding receptors and binding proteins are important in carcinogenesis for several tumours, but their expression pattern in the functionally and biologically heterogeneous human neuroendocrine tumours of the gastroenteropancreatic tract is largely unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>This study searched for the mRNA expression patterns of components of the IGF system: IGF\u20101 and IGF\u20102, IGF receptors 1 and 2 (IGF\u20101R, IGF\u20102R), IGF\u2010binding proteins 1\u20136 (IGFBP1\u20136)) in the most frequent human gastroenteropancreatic neuroendocrine tumours (gastrinomas, insulinomas, tumours associated with carcinoid syndrome and functionally inactive tumours) employing reverse transcriptase\u2010polymerase chain reaction (RT\u2010PCR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the 37 tumour samples analysed (nine gastrinomas, 10 insulinomas, nine tumours associated with carcinoid syndrome and nine functionally inactive tumours) IGFBP\u20102 was found in all tumour samples while the IGFBP\u20101 was expressed only at low frequency (10\u201322%) among the four tumour types. The IGF\u20102R was predominantly expressed in gastrinomas. Among the four tumour types the expression of IGF\u20101R, IGF\u20102R and IGFBP\u20106 varied significantly. In addition, 12 pairs of significantly coexpressed IGF system components were detected (IGF\u20101\u2003\u2194\u2003IGF\u20101R, IGF\u20101\u2003\u2194\u2003IGF\u20102R, IGF\u20101\u2003\u2194\u2003IGFBP\u20103, IGF\u20101\u2003\u2194\u2003IGFBP\u20106, IGFBP\u20103\u2003\u2194\u2003IGF\u20101R, IGFBP\u20106\u2003\u2194\u2003IGF\u20101R, IGFBP\u20101\u2003\u2194\u2003IGF\u20102R, IGFBP\u20103\u2003\u2194\u2003IGF\u20102R, IGFBP\u20105\u2003\u2194\u2003IGF\u20102R, IGFBP\u20103\u2003\u2194\u2003IGFBP\u20105, IGFBP\u20103\u2003\u2194\u2003IGFBP\u20106, IGFBP\u20105\u2003\u2194\u2003IGFBP\u20106).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The described differences of the expression patterns of the IGF system components in neuroendocrine tumour subtypes suggest tumour type\u2010dependent different pathways in tumour growth control by IGF system components.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2362.2000.00700.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T15:49:32Z","timestamp":1047397772000},"page":"729-739","source":"Crossref","is-referenced-by-count":62,"title":["mRNA expression patterns of insulin\u2010like growth factor system components in human neuroendocrine tumours"],"prefix":"10.1111","volume":"30","author":[{"family":"Wulbrand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Remmert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Z\u00f6fel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Wied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Fehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2362.2000.00700.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2362.2000.00700.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2362.2000.00700.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T17:55:45Z","timestamp":1698602145000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2362.2000.00700.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,8]]},"references-count":0,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2000,8]]}},"alternative-id":["10.1046\/j.1365-2362.2000.00700.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2362.2000.00700.x","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,8]]}}}